Abbott Opens New Research and Development Center in China

Abbott is expanding the company's research and development efforts.

No matter where you are in the world, people are looking for ways to maintain and improve their health. In China, Abbott (No. 14 on the DiversityInc Top 50 Companies list) is responding by expanding the company's research and development (R&D) efforts with the grand opening of a newly built, state-of-the-art R&D center in Shanghai. Built with an investment of more than $30 million (USD), the R&D center taps cutting-edge research to develop breakthrough products to help meet the evolving health and lifestyle needs of the local population.


The center, which spans 5,000 square meters (53,820 square feet) and consists of four floors, houses Abbott scientists with expertise related to the company's nutrition and diagnostics divisions under one roof. Prior to this new facility, the two organizations conducted their China R&D operations in a rented space in Shanghai.

Abbott nutrition scientists prepare a new product formulation for sensory testing.

In nutrition, scientists work with local researchers to better understand Chinese consumers' nutritional needs and preferences in order to create innovative science-based products. Researchers develop products for infants, children and aging adults. These products help people get the nutrition they need to live a healthy, active life. Researchers also create specially formulated products that can help people manage and overcome health conditions.

An Abbott diagnostics R&D scientist researches new substances (biomarkers) that may show the presence of disease at the R&D Center in Shanghai.

In diagnostics, the scientists conduct research and develop products for diagnosing and managing major diseases that seriously threaten the health of Chinese people such as infectious diseases, cancers, cardiovascular diseases, as well as endocrine and metabolic diseases. Researchers want to help drive local innovation and accelerate the discovery of new diagnostic tools using a multi-disciplinary, collaborative approach. In addition, Abbott's diagnostics business is building a customer-experience center across the street from the R&D facility to support the company's commitment to driving innovation in the country and also making it easier for local collaborations.

As the health needs of Chinese and global consumers evolve, Abbott continues to expand the company's scientific expertise and global R&D network to provide the latest technology and products so people can achieve optimal health and enjoy their best lives.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.